Valence8 US LP Makes New Investment in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Valence8 US LP purchased a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) in the third quarter, Holdings Channel reports. The institutional investor purchased 19,939 shares of the biotechnology company’s stock, valued at approximately $207,000.

Several other hedge funds also recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. bought a new position in Enanta Pharmaceuticals in the third quarter valued at about $122,000. Quest Partners LLC increased its stake in shares of Enanta Pharmaceuticals by 65.0% in the third quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock valued at $198,000 after buying an additional 7,535 shares during the period. US Bancorp DE raised its holdings in Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 4,243 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in Enanta Pharmaceuticals by 65.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock valued at $588,000 after buying an additional 18,003 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in Enanta Pharmaceuticals by 35.4% during the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock worth $362,000 after buying an additional 7,287 shares during the period. Institutional investors and hedge funds own 94.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ENTA shares. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th. JMP Securities reaffirmed a “market outperform” rating and set a $22.00 target price on shares of Enanta Pharmaceuticals in a report on Wednesday, October 9th. Evercore ISI raised Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th. Finally, JPMorgan Chase & Co. lowered their price objective on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a research report on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Enanta Pharmaceuticals Stock Up 3.0 %

ENTA stock opened at $9.35 on Friday. The firm has a market cap of $198.12 million, a price-to-earnings ratio of -1.72 and a beta of 0.56. The company’s fifty day simple moving average is $11.20 and its 200 day simple moving average is $12.45. Enanta Pharmaceuticals, Inc. has a 12-month low of $8.51 and a 12-month high of $17.80.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.